BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States through two segments: Pharmacy Solutions and Provider Services. Its platform delivers pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It also offers infused, injectable, and oral medication services, as well as patient-centric clinical home health care and rehabilitation services such as physical, speech, and occupational therapy and applied behavioral analysis. The company was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. Founded in 1974, it is headquartered in Louisville, Kentucky.
BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher
▲
Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.
This is the core new operational driver behind the company's raised guidance and stock rally.
▲
Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.
This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.
▼
IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.
This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.
▲
Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.
This is the key fundamental event that set the stage for the period's positive momentum.
Q3 2026
▲3▼1
BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher
▲
Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.
This is the core new operational driver behind the company's raised guidance and stock rally.
▲
Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.
This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.
▼
IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.
This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.
▲
Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.
This is the key fundamental event that set the stage for the period's positive momentum.
News & notes movingBTSG
United States
Biotech & Genomic Medicine▲
Bristol Myers Squibb Taps Onco360 for ZENBEXUS Myeloma Pharmacy Network
Bristol-Myers Squibb has selected Onco360 to join the restricted specialty pharmacy network for ZENBEXUS, its newly approved therapy for certain multiple myeloma patients. ZENBEXUS will be dispensed through a Risk Evaluation and Mitigation Strategy program, with Onco360 handling specialty dispensing and clinical support for eligible patients as the drug enters commercial rollout for an underserved group. The launch sits within Bristol-Myers Squibb's broader push in oncology therapies, where treatment access and safety controls are central to the business model, and the company carries a US$124.9b market cap. The company's narrative frames oncology launch execution as an offset to patent cliff risk, alongside global launches and commercial expansion of newer products. The practical test for investors will be ZENBEXUS uptake once the REMS network is fully operational, including disclosures on treated patient numbers within the eligible multiple myeloma population and updates on access or prescriber adoption tied to the Onco360 dispensing model.
Biotech & Genomic Medicine › Oncology Therapeutics ▲Demand
BMY · Demand · Positive Bristol-Myers Squibb selected Onco360 for the ZENBEXUS specialty pharmacy network, advancing commercial rollout and patient access for its newly approved myeloma therapy.
BTSG · Demand · Positive Onco360, part of BrightSpring Health Services, was chosen to join the restricted specialty pharmacy network dispensing ZENBEXUS, adding a new oncology dispensing relationship.
BrightSpring Sees $200M IRA Revenue Hit to Home and Community Pharmacy
BrightSpring Health Services' Home and Community Pharmacy segment expects the Inflation Reduction Act to cut its full-year 2026 revenues by approximately $200 million, even as the company holds its estimated EBITDA impact to roughly $15 million. In the second quarter, segment revenues fell 8% year over year to $540 million, with management attributing part of the decline to an approximately $50 million IRA impact during the quarter alongside the exit from certain uneconomic customers. Home and Community Pharmacy EBITDA still increased year over year in the second quarter, which management credited to operational process enhancements and the deployment of new technologies, with technology, automation and AI, Lean initiatives and procurement improvements central to that efficiency strategy. BrightSpring estimates the 2027 IRA impact on the segment will be roughly 50% of the 2026 impact, while it pursues regulatory, payer-contracting and operational measures to mitigate the pressure. Among peers, Cardinal Health has entered fiscal 2027 facing an estimated 500-basis-point Pharma revenue headwind from IRA pricing changes but expects little to no profit impact, while CVS Health reported Pharmacy & Consumer Wellness revenue pressure from regulatory price reductions even as adjusted operating income rose more than 10% year over year.
Aging Population › Home Healthcare & Hospice ▼Regulation
BTSG · Regulation · Negative BrightSpring expects the Inflation Reduction Act to cut its Home and Community Pharmacy segment's 2026 revenues by roughly $200 million.
CAH · Regulation · Negative Cardinal Health faces an estimated 500-basis-point Pharma revenue headwind in fiscal 2027 from IRA pricing changes, though it expects little to no profit impact.
CVS · Regulation · Negative CVS Health reported Pharmacy & Consumer Wellness revenue pressure from regulatory price reductions, even as adjusted operating income rose.
BrightSpring Health Services Sees 2026 Earnings Estimate Rise to $1.82 Per Share
Zacks Investment Research has raised its 2026 consensus earnings estimate for BrightSpring Health Services by 16 cents to $1.82 per share, implying 82% growth over the prior-year reported level, while the 2026 revenue consensus stands at $15.26 billion, an 18.2% improvement. The Louisville, Kentucky-based home and community-based healthcare platform, which carries a Zacks Rank #1 (Strong Buy) and an $11.62 billion market capitalization, is banking on expanding specialty pharmacy beyond oncology, infusion growth into another 12 to 15 states over the next five years, and deeper payer and hospital system relationships in Provider Services. BrightSpring shares have rallied 61% year to date, against a 3.2% gain for the industry and an 11.1% rise for the S&P 500, leaving its forward P/E of 32.35 well above the industry average of 16.92. Management expects the 2027 Inflation Reduction Act impact on Home and Community Pharmacy to be roughly half of the 2026 impact, though Specialty Pharmacy will continue to face revenue pressure, and integration of Amedisys and LHC plus automation and AI investments carry execution risk through 2026.
Aging Population › Home Healthcare & Hospice ▲Demand
BTSG · Capital · Positive Zacks raised its 2026 consensus EPS estimate by 16 cents to $1.82, implying 82% growth, and the stock carries a Strong Buy rank.
BrightSpring Health Services' Specialty and Infusion business grew revenue 30% year over year in the second quarter, with scripts up 31%, driven by branded limited distribution drug growth, new launches, fee-for-service programs, generics and acute-infusion expansion. The company added two ultra-narrow-network LDDs in the quarter, bringing its total portfolio to 155 programs, and launched 12 LDDs in the first half of 2026, four as exclusive partners and eight as ultra-narrow-network programs. Pharmacy Solutions' adjusted EBITDA rose 44% to $180 million, and management expects continued quarter-over-quarter growth through the remainder of 2026. BrightSpring said it has several hundred clinical liaisons across thousands of prescriber offices and 15 years of LDD experience, infrastructure it can leverage for rare and orphan therapies. Separately, Cigna's Specialty & Care pretax adjusted earnings rose 22% year over year to $1.1 billion, while Humana's second-quarter growth was driven primarily by Medicare Advantage membership and CenterWell expansion.
Zacks Investment Research highlights three non-tech Nasdaq-listed stocks with strong growth prospects for 2026. Interactive Brokers Group is expected to grow revenue and earnings by 18% and 22.8% respectively this year, with its consensus earnings estimate up 1.9% over the last 30 days. Roku's advertising revenue rose 24.8% year over year to $672.8 million in the second quarter of 2026, and its earnings estimate has improved 13.6% over the last month. BrightSpring Health Services is projected to grow revenue by 18.2% and earnings by 82% in 2026, with its earnings estimate up 8.3% over the last 30 days.
BrightSpring Stock Up Nearly 59% YTD on Strong Q2 Growth
BrightSpring Health Services stock has surged nearly 59% year to date, significantly outperforming the Medical Services industry's 1.7% gain and the S&P 500's 12.2% rise. The company reported second-quarter 2026 revenues rose 23% year over year to $3.9 billion, while adjusted EBITDA jumped 44% with margin expansion. BrightSpring also raised its 2026 EBITDA outlook, reduced leverage to 2.15x, and continued expanding its Specialty Pharmacy and Provider Services businesses. The Zacks Consensus Estimate for 2026 and 2027 earnings per share implies year-over-year growth of 78% and 24.5%, respectively, to $1.78 and $2.21. Management expects roughly $600 million in operating cash flow this year as AI and automation initiatives support long-term profitability.
BrightSpring Health Services lifts full-year revenue guidance to $15.26 billion
BrightSpring Health Services raised its full-year revenue guidance to $15.26 billion at the midpoint, up from $14.98 billion, after reporting second-quarter revenue of $3.87 billion that beat analyst estimates by 5.9%. Adjusted EPS of $0.45 exceeded expectations by 13%, and adjusted EBITDA of $205.5 million came in 5% above consensus. CEO Jon Rousseau highlighted 30% revenue growth and 31% script growth in the Specialty and Infusion pharmacy business, driven by new limited distribution drug launches, while acknowledging ongoing headwinds in the Home and Community Pharmacy segment from customer exits and regulatory pressures. The company also raised its full-year EBITDA guidance to $832.5 million at the midpoint, above analyst estimates of $816.3 million.
BrightSpring Health lifts 2026 guidance after Q2 revenue grows 23%
BrightSpring Health Services reported second-quarter 2026 net revenue of $3.873 billion, a 23.0% increase driven by volume gains and new-market expansion, and raised its full-year guidance. Adjusted EBITDA rose 44.2% to $205.5 million, with margin improving 80 basis points to 5.3%, while adjusted EPS reached $0.45 per diluted share. Pharmacy Solutions revenue grew 22% to $3.407 billion, led by branded limited-distribution drugs and acute infusion, and Provider Services revenue jumped 30% to $466 million, aided by home-health census growth and branch acquisitions. The company now expects full-year 2026 revenue of $15.1 billion to $15.425 billion, representing 17.0% to 19.5% growth, and adjusted EBITDA of $820 million to $845 million, up 32.8% to 36.8% year-over-year. BrightSpring also reported net debt of $1.7 billion as of June 30, 2026, with leverage reduced to 2.15x, and $120 million in share repurchases year-to-date.
Addus HomeCare to report Q2 earnings after Monday's close
Addus HomeCare will report its second-quarter results after the market closes on Monday. Analysts expect revenue to grow 7.7% year on year, a slowdown from the 21.8% increase in the same quarter last year. The company missed revenue estimates last quarter, reporting $363.6 million, though it beat earnings per share expectations. Peers BrightSpring Health Services and Chemed have already reported Q2 results, with BrightSpring posting 23% revenue growth and Chemed 8.8%, both exceeding analyst forecasts. Addus HomeCare shares have risen 9.2% over the past month and enter earnings with an average analyst price target of $133, compared to a current price of $115.48.
ADUS · Capital · Neutral Q2 earnings report upcoming; analysts expect revenue growth slowdown, but prior EPS beat and price target above current price.
BrightSpring Health Services Earnings Expected to Rise 68.2%
Wall Street expects BrightSpring Health Services to report quarterly earnings of $0.37 per share, a 68.2% year-over-year increase, on revenues of $3.65 billion, up 16%, when it releases results for the quarter ended June 2026 on July 31. The Zacks Consensus Estimate has been revised 2.25% lower over the last 30 days, and the Most Accurate Estimate is below the consensus, yielding an Earnings ESP of -1.35%. With a Zacks Rank of #3, the combination makes it difficult to conclusively predict an earnings beat, though the company has beaten consensus EPS estimates in three of the last four quarters. For comparison, industry peer Labcorp Holdings is expected to post earnings of $4.79 per share on revenues of $3.72 billion, with a positive Earnings ESP of +0.71% and a Zacks Rank of #2 suggesting a likely beat.
Seeking Alpha Quant rates Centene top healthcare stock, Doximity bottom ahead of Q2 earnings
Seeking Alpha's quantitative framework has identified Centene Corporation as the highest-rated healthcare stock with a Strong Buy rating of 4.97, while Doximity received the lowest rating of 1.21, a Strong Sell, as the second-quarter earnings season begins. The Health Care Select Sector SPDR Fund ETF, which tracks the sector and represents roughly 12.12% of the S&P 500, has risen 4.52% year-to-date, trailing the benchmark index's 10.06% advance. In the second quarter, the broader healthcare sector posted a modest 8.78% return, while the Technology index skyrocketed 43.49%. The top five Strong Buy stocks with market caps above $2 billion also include Liquidia Corporation at 4.95, BrightSpring Health Services at 4.95, LifeStance Health Group at 4.93, and PACS Group at 4.92. The bottom five Strong Sell or Sell stocks include TransMedics Group at 1.26, CSL Limited at 1.30, Zoetis at 1.34, and EssilorLuxottica ADR at 1.39.
Karman Holdings to join S&P SmallCap 600, replacing BrightSpring Health Services
Karman Holdings will join the S&P SmallCap 600 index, replacing BrightSpring Health Services, effective before trading on July 17, according to S&P Dow Jones Indices. The stock jumped 6.44% on the day of the announcement, though it remains down 44.51% over the past 90 days and 9.23% over the past year. A widely followed narrative on Simply Wall St pegs the stock as 53.8% undervalued with a fair value of $105.60 per share, far above the last close of $48.78, while a separate discounted cash flow model estimates a value of just $16.77 per share.
KRMN · Capital · Positive Karman Holdings is being added to the S&P SmallCap 600 index, which typically triggers buying by index funds and positive sentiment.
BTSG · Capital · Negative BrightSpring Health Services is being removed from the S&P SmallCap 600 index, which typically leads to forced selling by index funds and negative sentiment.
StockStory highlights BrightSpring Health Services as a cash-producing stock to watch, flags Palo Alto Networks and CDW as facing challenges
StockStory identifies BrightSpring Health Services as a cash-producing stock with solid fundamentals, citing its 22.6% annual revenue growth over the past two years, a $13.65 billion revenue base providing economies of scale, and a forecasted 14.1% revenue growth for the next 12 months. Meanwhile, Palo Alto Networks is flagged for its high servicing costs leading to a 72% gross margin and a 1.5 percentage point decline in operating margin over the last year, while CDW is noted for its 3.9% annual sales growth over five years and soft 3% estimated sales growth for the next 12 months, with earnings per share growth of only 2% trailing revenue gains.
BTSG · Demand · Positive BrightSpring Health Services is highlighted for strong revenue growth and solid fundamentals, indicating robust demand for its services.
CDW · Demand · Negative CDW is flagged for soft sales growth of 3% and low earnings per share growth, suggesting weak demand.
PANW · Pricing · Negative Palo Alto Networks is noted for high servicing costs leading to a 72% gross margin and declining operating margin, indicating pricing pressure.
BrightSpring Health Services Tops Q1 Senior Health, Home Health & Hospice Earnings
BrightSpring Health Services earned top marks among seven senior health, home health and hospice stocks tracked in the first quarter. The company reported revenues of $3.61 billion, up 25.6% year on year and beating analysts' expectations by 6.3%, while also exceeding EPS estimates and raising full-year EBITDA guidance. Chemed posted revenues of $657.5 million, a 1.6% increase that outperformed expectations by 1.2% and beat EPS estimates. Option Care Health was the weakest performer, with revenues of $1.35 billion missing estimates by 3.3% and full-year revenue guidance falling short. AdaptHealth reported $819.8 million in revenue, a 5.4% rise that beat estimates by 2.9%, though it missed EPS estimates significantly. Brookdale Senior Living saw revenues decline 6% to $764.9 million, missing estimates by 0.8% but beating EPS expectations. As a group, the seven companies' revenues beat consensus estimates by 0.9%, and their share prices have risen 7.6% on average since reporting.
BrightSpring Health Services Earns Zacks Strong Buy on Specialty and Provider Growth
BrightSpring Health Services has been named a Zacks Rank 1 Strong Buy, driven by strong momentum in its Specialty and Infusion segment and the integration of acquired home health assets. In the first quarter of 2026, Specialty and Infusion revenues surged 36% year over year to $2.64 billion, while Provider Services revenues rose 28% to $442 million, including a 49% jump in Home Health Care revenues to $266 million. The company raised its full-year adjusted EBITDA outlook, though it faces headwinds from the Inflation Reduction Act and brand-to-generic conversions expected to reduce 2026 revenues by roughly $600 million. BrightSpring shares have rallied 84.2% year to date, far outpacing the industry's 2.3% decline and the S&P 500's 8.9% gain.
BrightSpring Health Services Surges 79.4% Year-to-Date, Outpacing Medical Sector
BrightSpring Health Services, Inc. has gained about 79.4% so far this year, significantly outperforming the Medical sector's average return of negative 4.9%. The company currently holds a Zacks Rank of 1, or Strong Buy, and its full-year earnings consensus estimate has risen 10.8% over the past 90 days. Within the Medical Services industry, which has lost an average of 7.7% year-to-date, BrightSpring's performance stands out. Another medical stock, Bioventus, has returned 18.2% this year and carries a Zacks Rank of 2, or Buy, with its current-year EPS estimate up 0.6% over three months.
Senior Health and Hospice Stocks Beat Revenue Estimates in Q1
The seven senior health, home health, and hospice stocks tracked by StockStory reported a satisfactory first quarter, with aggregate revenues beating analysts' consensus estimates by 0.9%. Chemed posted revenues of $657.5 million, up 1.6% year on year and exceeding expectations by 1.2%, while BrightSpring Health Services was the best performer with revenues of $3.61 billion, a 25.6% increase that beat estimates by 6.3% and included a full-year EBITDA guidance raise. Option Care Health was the weakest, with revenues of $1.35 billion missing estimates by 3.3% and full-year revenue guidance falling short. Addus HomeCare reported revenues of $363.6 million, up 7.7% but 0.7% below expectations, and Brookdale posted revenues of $764.9 million, down 6% and 0.8% below estimates. On average, share prices of the group have been relatively unchanged since the latest earnings results.
USA